IBD
MCID: IRR002
MIFTS: 65

Irritable Bowel Syndrome (IBD)

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 73 36 42 44 15 62 17 70 32
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9778
KEGG 36 H01615
ICD9CM 34 564.1
MeSH 44 D043183
NCIt 50 C82343
SNOMED-CT 67 155783000
ICD10 32 K58 K58.0 K58.9
UMLS 70 C0022104

Summaries for Irritable Bowel Syndrome

KEGG : 36 Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to cyclic vomiting syndrome and fibromyalgia, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Irritable Bowel Syndrome is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Inflammatory bowel disease and Peptide ligand-binding receptors. The drugs Curcumin and Turmeric have been mentioned in the context of this disorder. Affiliated tissues include colon, brain and small intestine, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An intestinal disease that is characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

MedlinePlus : 42 Irritable bowel syndrome (IBS) is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. Although IBS can cause a great deal of discomfort, it does not harm the intestines. IBS is common. It affects about twice as many women as men and is most often found in people younger than 45 years. No one knows the exact cause of IBS. There is no specific test for it. Your doctor may run tests to be sure you don't have other diseases. These tests may include stool sampling tests, blood tests, and x-rays. Your doctor may also do a test called a sigmoidoscopy or colonoscopy. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

PubMed Health : 62 About irritable bowel syndrome: The typical symptoms of irritable bowel syndrome (IBS) include abdominal pain, constipation and diarrhea. Although IBS is not dangerous, the symptoms can be very painful and bothersome. Most people who have IBS have a mild form which they can cope with quite well without getting any treatment. But some people have symptoms that are so severe they significantly affect their everyday lives and cause distress. There is no cure for IBS. But over time, many people find out what helps and what makes things worse. And there are a number of different ways to relieve the symptoms.

Wikipedia : 73 Irritable bowel syndrome (IBS), referred to previously as spastic or nervous colon, and spastic bowel,... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 943)
# Related Disease Score Top Affiliating Genes
1 cyclic vomiting syndrome 32.5 IL6 HTR3A
2 fibromyalgia 32.5 TNF SLC6A4 IL6 IL1B IL10 HTR3A
3 interstitial cystitis 32.2 TRPV1 TAC1 IL6 CRHR2 CRHR1
4 allergic disease 32.0 TNF TLR4 IL6 IL1B IL10
5 constipation 31.9 VIP TRPV1 TAC1 SLC6A4 PYY MLN
6 gastroenteritis 31.8 TNF PYY MLN IL6 IL1B IL10
7 ulcerative colitis 31.8 TNF TLR4 IL6 IL1B IL10
8 food allergy 31.8 TNF TLR4 IL10
9 colitis 31.8 TNF TLR4 IL6 IL1B IL10
10 microscopic colitis 31.7 TNF TGM2 SLC6A4 IL6
11 depression 31.6 TPH1 SLC6A4 HTR3A CRHR1 CRH
12 crohn's disease 31.6 TNF TLR4 IL6 IL1B IL10
13 generalized anxiety disorder 31.6 TPH1 SLC6A4 HTR3A CRHR1
14 dysentery 31.5 TNF IL6 IL1B IL10
15 diarrhea 31.5 TPH1 TNF TLR4 TGM2 TAC1 SLC6A4
16 celiac disease 1 31.5 TNF TLR4 TGM2 PYY IL6 IL1B
17 peptic ulcer disease 31.4 TNF IL1B IL10
18 helicobacter pylori infection 31.4 TNF IL1B IL10
19 inflammatory bowel disease 31.4 VIP TNF TLR4 TAC1 PYY IL6
20 gastrointestinal system disease 31.4 MLN MIR24-1 HTR4 CCK
21 gastroesophageal reflux 31.3 VIP TNF PYY MLN IL6 IL1B
22 mood disorder 31.3 TPH1 SLC6A4 IL6 HTR3A CRHR2 CRHR1
23 post-traumatic stress disorder 31.3 SLC6A4 IL1B CRHR1 CRH
24 agoraphobia 31.3 SLC6A4 CRHR1 CRH
25 sclerosing cholangitis 31.3 TNF TLR4 IL6 IL10
26 cholangitis 31.3 TNF TLR4 IL6 IL10
27 somatization disorder 31.3 TAC1 SLC6A4 IL6 CRH
28 neurotic disorder 31.2 TNF SLC6A4 IL6
29 lymphocytic colitis 31.2 TNF TGM2 PYY
30 eating disorder 31.2 SLC6A4 PYY CRHR2 CRH CCK
31 esophagitis 31.2 TNF IL6 IL1B IL10
32 headache 31.2 TAC1 SLC6A4 CCK
33 acute stress disorder 31.1 SLC6A4 IL6 CRHR2 CRHR1 CRH
34 pouchitis 31.1 TNF TLR4
35 chronic fatigue syndrome 31.1 TNF TLR4 SLC6A4 IL6 IL1B IL10
36 rhinitis 31.1 VIP TNF IL6 IL10
37 severe acute respiratory syndrome 31.1 TNF TLR4 IL6 IL1B IL10
38 enterocolitis 31.1 TNF TLR4 IL6 IL10
39 dysthymic disorder 31.1 SLC6A4 IL6 CRH
40 prostatitis 31.1 TNF IL6 IL1B IL10
41 alcohol use disorder 31.0 SLC6A4 HTR3A CRHR1 CRH
42 dermatitis 31.0 TNF IL6 IL1B IL10
43 substance abuse 31.0 SLC6A4 IL6 CRHR1 CRH
44 proteasome-associated autoinflammatory syndrome 1 31.0 TNF TLR4 IL6 IL1B IL10
45 amebiasis 31.0 TNF IL1B IL10
46 gastritis 31.0 TNF TLR4 IL6 IL1B IL10
47 shigellosis 31.0 TNF TLR4 IL1B IL10
48 bacterial infectious disease 31.0 TNF TLR4 IL6 IL1B IL10
49 phobic disorder 31.0 SLC6A4 CRHR1 CRH
50 panic disorder 30.9 TPH1 TAC1 SLC6A4 HTR3A CRHR2 CRHR1

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety
Atrophic Gastritis Bronchitis
Deficiency Anemia Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Major Depressive Disorder Mitral Valve Disease
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:



Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas; vomiting following gastrointestinal surgery

MGI Mouse Phenotypes related to Irritable Bowel Syndrome:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 CCK CRH CRHR1 CRHR2 HTR3A HTR4
2 homeostasis/metabolism MP:0005376 10.36 CCK CRH CRHR1 CRHR2 HTR3A HTR4
3 cardiovascular system MP:0005385 10.31 CRHR1 CRHR2 IL10 IL1B IL6 SLC6A4
4 growth/size/body region MP:0005378 10.27 CRH HTR3A HTR4 IL10 IL1B IL6
5 endocrine/exocrine gland MP:0005379 10.26 CCK CRH CRHR1 CRHR2 HTR3A IL10
6 adipose tissue MP:0005375 10.18 CRH CRHR2 HTR4 IL6 PYY TLR4
7 immune system MP:0005387 10.18 CCK CRH CRHR2 HTR3A IL10 IL1B
8 integument MP:0010771 10.11 CRH HTR3A IL10 IL1B IL6 SLC6A4
9 nervous system MP:0003631 10.1 CCK CRH CRHR1 HTR3A HTR4 IL10
10 neoplasm MP:0002006 9.87 IL10 IL1B IL6 TGM2 TLR4 TNF
11 no phenotypic analysis MP:0003012 9.7 CCK CRH CRHR1 IL10 TGM2 TNF
12 renal/urinary system MP:0005367 9.56 CCK CRH HTR3A IL6 TAC1 TGM2
13 respiratory system MP:0005388 9.28 CRH CRHR1 HTR4 IL10 IL6 TLR4

Drugs & Therapeutics for Irritable Bowel Syndrome

PubMed Health treatment related to Irritable Bowel Syndrome: 62

There are a lot of different opinions about what can help relieve irritable bowel syndrome . Common recommendations include eating or avoiding certain foods and getting exercise . But most of this advice has not been tested in good-quality studies. If you ask different people who have IBS, it becomes clear that something that helps one person may end up making someone else’s symptoms worse. So it is best to try out different things and see for yourself if it helps. For example, someone who thinks that a particular type of food is making their symptoms worse can try to avoid eating it for a while. Some people have fewer symptoms if they eat their meals in smaller portions throughout the day. Keeping a diary can help you figure out whether doing specific things like exercising more or avoiding certain types of food have any effect. You can make a note of what you eat, how physically active you are, and how stressed you are over a longer period of time. It might be possible to recognize patterns after a while. There are also a number of different treatments that aim to relieve the symptoms. Because the causes of IBS are not clear, it is difficult to find suitable treatments. But research has suggested that at least some medications and treatments may help. Treatments for IBS include: Fiber supplements, for instance made from psyllium Peppermint oil Probiotics Anti-cramping medications Medications for constipation or diarrhea Various medications, such as antibiotics or antidepressants Psychological treatments , such as stress management or hypnosis Because medications in particular can have a number of side effects and sometimes even make the symptoms worse, it is worth carefully considering the potential advantages and disadvantages of taking them.

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
2
Turmeric Approved, Experimental, Investigational Phase 4
3
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
4
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
5
Alverine Approved, Investigational Phase 4 150-59-4 3678
6
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
7
Alosetron Approved, Withdrawn Phase 4 122852-42-0 2099
8
Ondansetron Approved Phase 4 99614-02-5 4595
9
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
10
Trimebutine Approved Phase 4 39133-31-8
11
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
12
Pancrelipase Approved, Investigational Phase 4 53608-75-6
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
15
Tegaserod Approved, Investigational, Withdrawn Phase 4 189188-57-6, 145158-71-0 122724
16
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
17
Lactulose Approved Phase 4 4618-18-2 11333
18
Metronidazole Approved Phase 4 443-48-1 4173
19
Clarithromycin Approved Phase 4 81103-11-9 84029
20
Linaclotide Approved Phase 4 851199-59-2 65351
21
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
22
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
23
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Tiropramide Investigational Phase 4 55837-29-1 42262
26
Ramosetron Investigational Phase 4 132036-88-5
27
Fenoverine Investigational Phase 4 37561-27-6
28
Daidzein Experimental Phase 4 486-66-8 5281708
29
Genistein Investigational Phase 4 446-72-0 5280961
30 Vasodilator Agents Phase 4
31 Phosphodiesterase Inhibitors Phase 4
32 Radiation-Protective Agents Phase 4
33 Platelet Aggregation Inhibitors Phase 4
34 Guar Phase 4
35 Vitamins Phase 4
36 (1-6)-alpha-glucomannan Phase 4
37 Gastrointestinal Agents Phase 4
38 Manna Phase 4
39 Dopamine Agents Phase 4
40 Duloxetine Hydrochloride Phase 4
41
Histamine Phosphate Phase 4 51-74-1 65513
42 Histamine H1 Antagonists Phase 4
43 Histamine Antagonists Phase 4
44 Trace Elements Phase 4
45 Micronutrients Phase 4
46 calcium channel blockers Phase 4
47 Antimetabolites Phase 4
48 Lipid Regulating Agents Phase 4
49 Hypolipidemic Agents Phase 4
50 Calciferol Phase 4

Interventional clinical trials:

(show top 50) (show all 709)
# Name Status NCT ID Phase Drugs
1 Effect of Pentoxifylline on Tight Junctions of Intestinal Mucosa in Patients With Irritable Bowel Syndrome Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
2 Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo Unknown status NCT02573844 Phase 4 Proklama
3 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome: A Randomized, Double-blinded,Placebo- Controlled Multicenter Study Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
4 Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome Unknown status NCT03557788 Phase 4 Rifaximin Oral Tablet
5 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
6 Peripheral Histamine 1 Receptor Blockade in IBS Unknown status NCT01908465 Phase 4 Ebastine;Placebo
7 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
8 Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
9 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
10 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
11 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
12 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
13 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
14 Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
15 Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial Completed NCT01495806 Phase 4 Glucomannan;placebo
16 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
17 Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of Mebeverine, Methylcellulose, Placebo and a Patient Self-management Cognitive Behavioural Therapy Website. (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
18 A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects Completed NCT00370032 Phase 4 alosetron
19 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
20 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
21 Randomised Controlled Trial: Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
22 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
23 IBS Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
24 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
25 Efficacy Evaluation of Enterogermina, 2 Billion Bacillus Clausii Spores, on Eradication of Small Intestinal Bacterial Overgrowth: a Randomised, Parallel-group, Open Study. Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
26 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
27 Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial Completed NCT01507922 Phase 4 Fenoverine;Timebutine
28 A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF) Completed NCT02959983 Phase 4 Eluxadoline;Placebo
29 Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation Completed NCT01331213 Phase 4 Pregabalin;Placebo
30 Efficacy and Safety of Saccharomyces Boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Patients Suffering From Irritable Bowel Syndrome With Diarrhea Completed NCT04627337 Phase 4 Saccharomyces Boulardii 250 MG
31 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
32 Supplementation With a Multi-strain Probiotic Formulation (Bio-Kult®) in the Management of Diarrhea-predominant Irritable Bowel Syndrome - a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT03251625 Phase 4 Probiotic Formula Capsule
33 Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
34 An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation. Completed NCT02590432 Phase 4 Linaclotide
35 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
36 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
37 Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language) Completed NCT02077699 Phase 4
38 Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D). Completed NCT01316718 Phase 4 Mesalazine;Placebo
39 3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM) Completed NCT03441581 Phase 4 Eluxadoline
40 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the "Responder" Completed NCT00745004 Phase 4 Ondansetron;Placebo
41 A Randomized Controlled Trial to Evaluate the Short-term Efficacy and Long-term Health Economic Impact of a Dietary Intervention Compared to Pharmacotherapy With a Musculotropic Spasmolytic Agent for Newly Diagnosed or Newly Treated Irritable Bowel Syndrome in Primary Care Completed NCT04270487 Phase 4 Otilonium Bromide
42 Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico Completed NCT04145856 Phase 4
43 Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome Completed NCT02111603 Phase 4 Colesevelam
44 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
45 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
46 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
47 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
48 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
49 Mode of Action of Moviprep:Impact on Distribution of Intestinal Fluid and Colonic Microbiota Completed NCT01622972 Phase 4 Polyethyleneglycol
50 Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Recruiting NCT04656730 Phase 4 Iberogast® and Iberogast® N

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alosetron
alosetron hydrochloride
calcium polycarbophil
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Propantheline
Propantheline Bromide
Psyllium
PSYLLIUM HYDROCOLLOID
tegaserod
Tegaserod maleate

Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

40
Colon, Brain, Small Intestine, Spinal Cord, Smooth Muscle, Amygdala, Pituitary

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 13409)
# Title Authors PMID Year
1
Effectiveness of Tong-Xie-Yao-Fang combined with Si-Ni-San for irritable bowel syndrome: A protocol for systematic review and meta-analysis. 42 61
33726014 2021
2
To assess the effective and safety of compound glutamine entersoluble capsules in irritable bowel syndrome: A protocol for systematic review and meta-analysis. 61 42
33725903 2021
3
Xiaoyao-san, a traditional Chinese herbal formula, for the treatment of irritable bowel syndrome: A protocol for a systematic review and meta-analysis. 42 61
33725813 2021
4
The effects of tegaserod, a gastrokinetic agent, on voltage-gated K+ channels in rabbit coronary arterial smooth muscle cells. 61
33620095 2021
5
Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways. 61
33592255 2021
6
Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. 61
33745570 2021
7
Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis. 61
33326819 2021
8
Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine. 61
33795545 2021
9
Lactose Sensitivity and Lactose Malabsorption: The 2 Faces of Lactose Intolerance. 61
33361550 2021
10
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. 61
33811041 2021
11
[Functional Exams in the gastroenterology - new developments and tips for the common practice]. 61
33780988 2021
12
Targeted pharmacotherapy of irritable bowel syndrome. 61
33481423 2021
13
Oridonin Attenuates TNBS-induced Post-inflammatory Irritable Bowel Syndrome via PXR/NF-κB Signaling. 61
33125572 2021
14
Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia. 61
33795538 2021
15
Online Education Is Non-Inferior to Group Education for Irritable Bowel Syndrome: A Randomized Trial and Patient Preference Trial. 61
32289541 2021
16
Psychological defense mechanisms and use of corporeal discourse: a comparison between patients with irritable bowel syndrome, medical personnel and healthy volunteers. 61
32956177 2021
17
Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome. 61
33797165 2021
18
How are perceptions of social strain and low support related to Irritable Bowel Syndrome?-A Norwegian twin study. 61
33030285 2021
19
A Resting-state Functional Magnetic Resonance Imaging Study of Whole-brain Functional Connectivity of Voxel Levels in Patients With Irritable Bowel Syndrome With Depressive Symptoms. 61
33795543 2021
20
Association between pain sensitivity and gray matter properties in the sensorimotor network in women with irritable bowel syndrome. 61
33174312 2021
21
Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use. 61
32677464 2021
22
Effects of stress-related peptides on chloride secretion in the mouse proximal colon. 61
33118282 2021
23
Sex Hormones, BDNF, Leptin, and TGF-β1 in Females With IBS: A Pilot Investigation. 61
32806924 2021
24
Mast Cell Activation Syndrome: A Primer for the Gastroenterologist. 61
32328892 2021
25
When Eating Becomes a Pain in the Gut. 61
33674226 2021
26
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. 61
33810796 2021
27
Impact of Overlapping Functional Gastrointestinal Disorders on the Quality of Life in Patients With Gastroesophageal Reflux Disease. 61
33795540 2021
28
Heartburn in children and adolescents in the presence of functional dyspepsia and/or irritable bowel syndrome correlates with the presence of sleep disturbances, anxiety, and depression. 61
33787652 2021
29
Is Celiac Disease Testing Necessary in Functional Abdominal Disorders? A Study in Predominantly Latino Children. 61
33230076 2021
30
Colonic paracellular permeability and circulating zonulin-related proteins. 61
33535002 2021
31
Dietary gluten avoidance in Canada: a cross-sectional study using survey data. 61
33795221 2021
32
Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study. 61
33186771 2021
33
Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome. 61
33797116 2021
34
Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. 61
33566707 2021
35
Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide. 61
33769858 2021
36
Central regulatory mechanisms of visceral sensation in response to colonic distension with special reference to brain orexin. 61
33636498 2021
37
Continuing Medical Education Questions: March 2021: Irritable Bowel Syndrome in. 61
33657036 2021
38
Are Faecal Microbiota Analyses on Species-Level Suitable Clinical Biomarkers? A Pilot Study in Subjects with Morbid Obesity. 61
33806783 2021
39
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. 61
33807115 2021
40
Peripheral Guanylate Cyclase-C modulation of corticolimbic activation and corticotropin-releasing factor signaling in a rat model of stress-induced colonic hypersensitivity. 61
33373484 2021
41
PROBIOTICS IN GASTROINTESTINAL DISEASES: ALL THAT GLITTERS IS NOT GOLD. 61
33752212 2021
42
Bugs and Brains, the Gut and Mental Health Study: a mixed-methods study investigating microbiota composition and function in anxiety, depression and irritable bowel syndrome. 61
33722869 2021
43
Impact of COVID-19 on Individuals With Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression. 61
33780216 2021
44
Dopa responsive irritable bowel syndrome: restless bowel syndrome or a gastrointestinal variant of restless legs syndrome? 61
33762285 2021
45
Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. 61
32324678 2021
46
The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease. 61
33303315 2021
47
Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease. 61
33177381 2021
48
(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. 61
33805938 2021
49
Quantitative Analysis of Intramucosal Mast Cells in Irritable Bowel Syndrome: A Comparison With Inflammatory Bowel Disease in Remission. 61
32649443 2021
50
Irritable bowel syndrome and lactose intolerance: the importance of differential diagnosis. A monocentric study. 61
32623873 2021

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

Pathways related to Irritable Bowel Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Inflammatory bowel disease hsa05321

Pathways related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 VIP TRPV1 TAC1 PYY MLN HTR4
2
Show member pathways
12.58 TNF TLR4 IL6 IL1B IL10
3
Show member pathways
12.57 TNF TLR4 IL6 IL1B IL10
5
Show member pathways
12.28 TNF TLR4 IL6 IL1B
6
Show member pathways
12.24 TNF TLR4 IL1B IL10
7 12.22 TNF TLR4 IL6 IL1B
8 12.21 TNF TLR4 IL6 IL1B IL10
9
Show member pathways
12.19 TNF IL6 IL1B IL10
10
Show member pathways
12.17 TNF TLR4 IL6 IL1B
11 12.09 VIP HTR4 CRHR2 CRHR1 CRH
12 12.03 TNF TLR4 IL6 IL1B IL10
13 12 TNF TLR4 IL6 IL1B
14 11.97 TPH1 SLC6A4 HTR4 HTR3A
15 11.96 TNF IL6 IL1B IL10
16 11.86 TNF TLR4 IL6 IL1B
17 11.85 TLR4 CRHR2 CRHR1 CRH
18 11.84 TNF TLR4 IL6 IL1B IL10
19 11.76 TNF IL1B IL10
20 11.74 TNF IL6 IL1B IL10
21 11.67 TNF TLR4 IL6 IL10
22
Show member pathways
11.65 TNF IL6 IL1B
23 11.64 TNF IL6 IL1B
24
Show member pathways
11.6 TNF TLR4 IL6 IL1B IL10
25 11.59 TNF TLR4 IL6 IL1B
26 11.54 TNF TLR4 IL6 IL1B IL10
27 11.5 TNF TLR4 IL1B
28 11.5 TNF IL6 IL1B IL10
29 11.47 TNF IL6 IL1B
30
Show member pathways
11.44 TNF SLC6A4 IL1B
31 11.43 TPH1 TNF TAC1 SLC6A4 IL6 IL1B
32 11.33 TNF IL6 IL1B IL10
33 11.3 TNF IL6 IL1B
34 11.28 TNF IL6 IL1B
35 11.25 TNF TLR4 IL6 IL1B IL10
36 11.17 TNF IL6 IL1B IL10
37 11.12 TPH1 SLC6A4 HTR4 HTR3A
38 10.9 TNF TLR4 IL6 IL1B IL10
39 10.76 IL6 IL1B
40 10.51 VIP CCK
41 10.5 CRHR2 CRHR1 CRH

GO Terms for Irritable Bowel Syndrome

Cellular components related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.92 TRPV1 TNF TLR4 SLC6A4 HTR4 HTR3A
2 extracellular space GO:0005615 9.91 TNF TAC1 PYY MIR24-1 IL6 IL1B
3 synapse GO:0045202 9.88 TRPV1 TAC1 SLC6A4 HTR4 HTR3A CRH
4 extracellular region GO:0005576 9.85 VIP TNF TAC1 PYY MLN IL6
5 neuronal cell body GO:0043025 9.77 TRPV1 TAC1 HTR3A CRH CCK
6 neuron projection GO:0043005 9.43 VIP TRPV1 TPH1 SLC6A4 HTR3A CRHR1
7 intrinsic component of plasma membrane GO:0031226 8.92 TRPV1 TLR4 TGM2 CRHR1

Biological processes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.06 TNF TLR4 SLC6A4 IL6 IL1B CRH
2 positive regulation of apoptotic process GO:0043065 10.05 TRPV1 TNF TGM2 IL6 CCK
3 immune response GO:0006955 10.04 TNF TLR4 IL6 IL1B IL10 CRHR1
4 chemical synaptic transmission GO:0007268 10.01 TAC1 HTR4 HTR3A CRH
5 signal transduction GO:0007165 10 VIP TLR4 IL6 IL1B IL10 HTR4
6 G protein-coupled receptor signaling pathway GO:0007186 9.97 VIP TAC1 PYY MLN HTR4 CRHR2
7 response to lipopolysaccharide GO:0032496 9.96 TLR4 TAC1 IL1B IL10
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.94 TNF TLR4 IL6 IL1B
9 positive regulation of JNK cascade GO:0046330 9.88 TNF TLR4 IL1B
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TNF IL6 IL1B IL10
11 regulation of insulin secretion GO:0050796 9.87 TNF IL6 IL1B
12 negative regulation of interleukin-6 production GO:0032715 9.87 TNF TLR4 IL10
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF TLR4 IL1B
14 response to glucocorticoid GO:0051384 9.86 TNF IL6 IL10
15 positive regulation of interferon-gamma production GO:0032729 9.85 TNF TLR4 IL1B
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF TGM2 IL6
17 positive regulation of interleukin-1 beta production GO:0032731 9.84 TNF TLR4 IL6
18 positive regulation of inflammatory response GO:0050729 9.83 TNF TLR4 TGM2 IL1B
19 cellular response to lipopolysaccharide GO:0071222 9.83 TNF TLR4 IL6 IL1B IL10
20 negative regulation of interferon-gamma production GO:0032689 9.81 TLR4 MIR24-1 IL10
21 positive regulation of interleukin-6 production GO:0032755 9.81 TNF TLR4 IL6 IL1B
22 positive regulation of chemokine production GO:0032722 9.8 TNF TLR4 IL6
23 regulation of sensory perception of pain GO:0051930 9.78 VIP IL10 CCK
24 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL6 IL10
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TNF TLR4 IL1B
26 negative regulation of neurogenesis GO:0050768 9.72 TNF IL6 IL1B
27 negative regulation of heart rate GO:0010459 9.71 TRPV1 TAC1
28 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.71 TNF TLR4 IL6
29 positive regulation of interleukin-8 production GO:0032757 9.71 TNF TLR4 IL6 IL1B
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 TLR4 IL10
31 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.7 TNF TLR4
32 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
33 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
34 parturition GO:0007567 9.69 CRHR1 CRH
35 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
36 positive regulation of lymphocyte proliferation GO:0050671 9.68 TLR4 TAC1
37 positive regulation of behavioral fear response GO:2000987 9.67 CRH CCK
38 positive regulation of glial cell proliferation GO:0060252 9.67 TNF IL6 IL1B
39 negative regulation of cytokine production involved in immune response GO:0002719 9.66 TNF IL10
40 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.65 CRHR2 CRHR1
41 response to pain GO:0048265 9.65 TRPV1 TAC1 CRH
42 positive regulation of fever generation GO:0031622 9.64 TNF IL1B
43 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B IL10
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 TNF IL1B
46 fever generation GO:0001660 9.61 TRPV1 IL1B
47 positive regulation of corticosterone secretion GO:2000854 9.56 TAC1 CRH
48 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
49 positive regulation of nitric oxide biosynthetic process GO:0045429 9.46 TRPV1 TNF TLR4 IL1B
50 inflammatory response GO:0006954 9.17 TRPV1 TNF TLR4 TAC1 IL6 IL1B

Molecular functions related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.77 TRPV1 TLR4 HTR3A CRHR2 CRHR1
2 cytokine activity GO:0005125 9.73 TNF IL6 IL1B IL10
3 peptide hormone receptor binding GO:0051428 9.4 VIP CCK
4 hormone activity GO:0005179 9.35 VIP PYY MLN CRH CCK
5 serotonin binding GO:0051378 9.33 SLC6A4 HTR4 HTR3A
6 corticotropin-releasing hormone receptor activity GO:0043404 9.32 CRHR2 CRHR1
7 corticotrophin-releasing factor receptor activity GO:0015056 9.26 CRHR2 CRHR1
8 neuropeptide hormone activity GO:0005184 8.92 VIP PYY CRH CCK

Sources for Irritable Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....